Tonix Pharma (TNXP) has released an update.
On January 29, 2024, the FDA conditionally accepted the trade name Tonmya™ for the Company’s TNX-102 SL, aimed at managing fibromyalgia. The Company’s report includes forward-looking statements regarding product development, clinical trials, and potential market opportunities, based on current industry estimations and management beliefs. These statements are subject to various risks and uncertainties that could cause actual results to differ from projections, and the Company cautions investors from relying solely on these projections.
For further insights into TNXP stock, check out TipRanks’ Stock Analysis page.
